Alliance Global Partners lowered the firm’s price target on Imunon to $12 from $15 and keeps a Buy rating on the shares. The analyst cites the company’s increased shares outstanding for the target drop. It believes IMNN-001 showed promise in Phase 2 with a benefit in overall survival for ovarian cancer patients.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- 3 Penny Stocks to Watch Now, 8/1/24
- Imunon to sell 5M shares at $2.00 in registered direct offering
- IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Imunon Reports Promising Phase 2 Ovarian Cancer Trial Results
- Imunon announces increase in survival in patients treated with IMNN-001